SeerSEER -1.81%53 Days Payable is 204.27 as of Mar. 2026, which is 33% above its 10-year median of 153.67. GuruFocus rates SEER with a GF Score™ of 53/100 and a GF Value™ of $2.19 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 703 Biotechnology companies, Seer ranks better than 61.31% on this metric.
Seer's average Accounts Payable for the
three
months ended in Mar. 2026 was $4.05 Mil. Seer's Cost of Goods Sold for the
three
months ended in Mar. 2026 was $1.81 Mil.
Hence, Seer's Days Payable for the
three
months ended in Mar. 2026 was 204.27.
The historical rank and industry rank for Seer's Days Payable or its related term are showing as below:
SEER'
s Days Payable Range Over the Past 10 Years
Min: 77.74 Med: 153.67 Max: 336.19
Current: 182.88
During the past 8 years, Seer's highest Days Payable was 336.19. The lowest was 77.74. And the median was 153.67.
SEER's Days Payable is ranked better than 61.31% of 703
companies
in the Biotechnology industry
Industry Median: 113.76
vs SEER: 182.88
Seer's Days Payable
increased
from Mar. 2025 (193.03) to Mar. 2026 (204.27).
It may suggest that Seerdelayed paying its suppliers.
Seer Days Payable Related Terms
Seer Days Payable Historical Data
* Premium members only.
The historical data trend for Seer's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Seer's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Seer Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Seer's Days Payable distribution charts can be found below:
* The bar in red indicates where Seer's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Seer's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Seer (SEER) has a Days Payable of 204.27 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Seer and its competitors. This is 33% above median its historical median of 153.67. Over the past decade, Seer's Days Payable has ranged from 77.74 to 336.19. According to the industry distribution chart, Seer ranks #272 out of 703 companies in the Biotechnology industry, placing it in the top 38.7%.
Is Seer's Days Payable too high?
Seer's current Days Payable of 204.27 is 33% above median its 10-year median of 153.67. Over the past 10 years, this metric has ranged from a low of 77.74 to a high of 336.19. The Biotechnology industry median Days Payable is 113.76. Seer's value of 204.27 is 79.6% above this industry median. Based on the distribution chart, Seer ranks #272 out of 703 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Seer has a GF Score™ of 53/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Seer's Days Payable compare to CSBR and RLYB?
According to the Biotechnology industry distribution chart, Seer ranks #272 out of 703 companies for Days Payable. This puts Seer in the upper half of its industry. The industry median Days Payable is 113.76. Seer's value of 204.27 is 79.6% above this benchmark. Historically, Seer's own Days Payable has ranged from 77.74 to 336.19 over the past decade. While the company's 10-year median is 153.67 vs. the industry median of 113.76, Seer has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.76, based on 703 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Seer's current Days Payable of 204.27 is 79.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Seer and its competitors. For the Biotechnology industry, the median Days Payable is 113.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Seer's current Days Payable is 204.27, which is 33% above median its own 10-year median of 153.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Seer stock overvalued right now?
Based on GuruFocus' analysis, Seer (SEER) is currently considered Modestly Undervalued. The stock's GF Value™ is $2.19, compared to a current price of $1.63 — trading 25.6% below its estimated fair value. The current Days Payable is 204.27, which is 33% above median its 10-year median of 153.67 and 79.6% above the Biotechnology industry median of 113.76. Seer's overall GF Score™ is 53/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Seer (SEER), the current Days Payable is 204.27 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Seer (SEER) Overvalued in 2026?
Based on GuruFocus' analysis, Seer stock appears to be undervalued.
The current stock price of $1.63 is trading 25.6% below its estimated GF Value™ of $2.19.
GuruFocus considers Seer to be Modestly Undervalued.
Key valuation signals for SEER:
Days Payable: 204.27 (33% above median its 10-year median of 153.67)
GF Value™: $2.19 vs. price of $1.63 (25.6% below fair value)
Industry Position: 79.6% above the Biotechnology median (#272 of 703)
No single metric tells the full story. See the SEER stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Seer Inc is a life sciences company, develops and commercializes products to decode the biology of the proteome. The company offers Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and data analysis software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only. It markets and sells its products for research use only, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. The company operates in China, Australia, Eastern Europe, Israel, Japan and South Africa.
53GF Score
Get the complete analysis for SEER
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SEER has been successfully added to your 
